Literature DB >> 21798887

Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Matthieu Peyre1, Stephane Goutagny, Sandrine Imbeaud, Alexis Bozorg-Grayeli, Michele Felce, Olivier Sterkers, Michel Kalamarides.   

Abstract

Surgical management of bilateral vestibular schwannomas (VS) in neurofibromatosis type 2 (NF2) is often difficult, especially when both tumors threaten the brainstem. When the largest tumor has been removed, the management of the contralateral VS may become puzzling. To give new insights into the growth pattern of these tumors and to determine the best time point for treatment (surgery or medical treatment), we studied radiological growth in 11 VS (11 patients with NF2) over a long period (mean duration, 7.6 years), before and after removal of the contralateral tumor while both were threatening the brainstem. We used a quantitative approach of the radiological velocity of diametric expansion (VDE) on consecutive magnetic resonance images. Before first surgery, growth patterns of both tumors were similar in 9 of 11 cases. After the first surgery, VDE of the remaining VS was significantly elevated, compared with the preoperative period (2.5 ± 2.2 vs 4.4 ± 3.4 mm/year; P = .01, by Wilcoxon test). Decrease in hearing function was associated with increased postoperative growth in 3 cases. Growth pattern of coexisting intracranial meningiomas was not modified by VS surgery on the first side. In conclusion, removal of a large VS in a patient with NF2 might induce an increase in the growth rate of the contralateral medium or large VS. This possibility should be integrated in NF2 patient management to adequately treat the second VS.

Entities:  

Mesh:

Year:  2011        PMID: 21798887      PMCID: PMC3177662          DOI: 10.1093/neuonc/nor101

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  27 in total

1.  New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma.

Authors:  Jin Kanzaki; Mirko Tos; Mario Sanna; David A Moffat; Edwin M Monsell; Karen I Berliner
Journal:  Otol Neurotol       Date:  2003-07       Impact factor: 2.311

2.  Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2.

Authors:  M M Abaza; E Makariou; M Armstrong; A K Lalwani
Journal:  Laryngoscope       Date:  1996-06       Impact factor: 3.325

3.  Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods.

Authors:  J C Flickinger; D Kondziolka; A Niranjan; L D Lunsford
Journal:  J Neurosurg       Date:  2001-01       Impact factor: 5.115

4.  Continuous growth of mean tumor diameter in a subset of grade II gliomas.

Authors:  Emmanuel Mandonnet; Jean-Yves Delattre; Marie-Laure Tanguy; Kristin R Swanson; Antoine F Carpentier; Hugues Duffau; Philippe Cornu; Rémy Van Effenterre; Ellsworth C Alvord; Laurent Capelle
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

5.  Clinicopathological factors related to regrowth of vestibular schwannoma after incomplete resection.

Authors:  Masafumi Fukuda; Makoto Oishi; Tetsuya Hiraishi; Manabu Natsumeda; Yukihiko Fujii
Journal:  J Neurosurg       Date:  2011-01-07       Impact factor: 5.115

6.  Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study.

Authors:  Victor-Felix Mautner; Michael E Baser; Sarang D Thakkar; Urs M Feigen; J M Friedman; Lan Kluwe
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

7.  Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.

Authors:  Michael E Baser; Erini V Makariou; Dilys M Parry
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

8.  Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas.

Authors:  K Saito; M Kato; N Susaki; T Nagatani; T Nagasaka; J Yoshida
Journal:  Clin Neuropathol       Date:  2003 Jan-Feb       Impact factor: 1.368

9.  Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis.

Authors:  J G Rowe; M W R Radatz; L Walton; T Soanes; J Rodgers; A A Kemeny
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

10.  Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects.

Authors:  William H Slattery; Laurel M Fisher; Zarina Iqbal; Mark Oppenhiemer
Journal:  Otol Neurotol       Date:  2004-09       Impact factor: 2.311

View more
  4 in total

1.  Connexin 43 maintains tissue polarity and regulates mitotic spindle orientation in the breast epithelium.

Authors:  D Bazzoun; H A Adissu; L Wang; A Urazaev; I Tenvooren; S F Fostok; S Chittiboyina; J Sturgis; K Hodges; G Chandramouly; P-A Vidi; R S Talhouk; S A Lelièvre
Journal:  J Cell Sci       Date:  2019-05-16       Impact factor: 5.285

Review 2.  The Role of Extracellular Vesicles in Cancer-Nerve Crosstalk of the Peripheral Nervous System.

Authors:  Yuanning Guo; Ziv Gil
Journal:  Cells       Date:  2022-04-11       Impact factor: 7.666

3.  Age-related schwannomatosis with potential exosome-mediated contribution to prostate hyperplasia: a case report and mini-review.

Authors:  Bérengère Chignon-Sicard; Véronique Hofman; Daniel Chevallier; Jean-Michel Cucchi; Marius Ilié; Bérengère Dadone-Montaudié; Florence Paul; Xavier Carpentier; Hervé Quintens; Coraline Bence-Gauchiez; Didier Caselles; Jacqueline Rossant; Matthieu Durand; Roger Bertolotti
Journal:  Ther Adv Urol       Date:  2019-09-26

4.  Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.

Authors:  Isabel Gugel; Julian Zipfel; Philip Hartjen; Lan Kluwe; Marcos Tatagiba; Victor-Felix Mautner; Martin Ulrich Schuhmann
Journal:  Childs Nerv Syst       Date:  2020-06-16       Impact factor: 1.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.